Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib.
Multiple myeloma (MM) is a neoplastic lymphoproliferative disorder characterized by uncontrolled monoclonal plasma cell proliferation. Among different isotypes of MM, immunoglobulin D (IgD) MM is very rare, representing only 1 to 2% of all isotypes. Chronic myelogenous leukemia (CML) is a neoplastic myeloproliferative disorder of pluripotent hematopoietic stem cell, which is characterized by the uncontrolled proliferation of myeloid cells. An 88-year-old male was diagnosed simultaneously with IgD kappa MM and CML. A distinctive feature in this patient was the progression to plasma cell leukemia without any symptomatic myeloma stage. He was treated simultaneously with lenalidomide, bortezomib and imatinib. Synchronous occurrence of these rare hematological malignancies in a single patient is an exceedingly rare event. Multiple hypotheses to explain co-occurrence of CML and MM have been proposed; however, the exact etiological molecular pathophysiology remains elusive.
Departments of Internal Medicine, Abington Memorial Hospital/Abington-Jefferson Health , PA, USA.
Naveed
N
Ali
Departments of Hematology and Oncology, Abington Memorial Hospital/Abington-Jefferson Health , PA, USA.
Peter V
PV
Pickens
Departments of Pathology, Abington Memorial Hospital/Abington-Jefferson Health , PA, USA.
Herbert E
HE
Auerbach
Immunoglobulin D multiple myeloma; bortezomib; chronic myelogenous leukemia; imatinib; plasma cell leukemia